epirubicin has been researched along with Rhabdoid Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, J; Lei, L; Li, T; Li, Z; Liu, P; Wang, J; Wang, X; Yan, H; Yang, B | 1 |
| Ajioka, Y; Banzai, C; Fujita, K; Kashima, K; Motoyama, T; Nishikura, K; Sasahara, J; Tanaka, K; Yahata, T | 1 |
2 other study(ies) available for epirubicin and Rhabdoid Tumor
| Article | Year |
|---|---|
Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
Topics: Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epirubicin; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Insulin-Like Growth Factor II; Models, Biological; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptor, IGF Type 2; Rhabdoid Tumor; Signal Transduction; SMARCB1 Protein; Stress, Physiological; Tumor Microenvironment | 2017 |
Advanced malignant rhabdoid tumor of the ovary effectively responding to chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Ifosfamide; Ovarian Neoplasms; Rhabdoid Tumor | 2007 |